Numerous large randomized trials have demonstrated the efficacy of CGM use in individuals with T1D6–12 and insulin-treated T2D.13,14 Specific benefits include reductions in A1c and glycemic variability; increased time in target glycemic range; decreased time in hypoglycemic range; and fewer hypoglycemic events. This evidence concerns the gene INS and type 2 diabetes mellitus.